Mousa SA - Search Results

1

(Thyroid) Hormonal regulation of breast cancer cells.

Hercbergs A, Lin HY, Mousa SA, Davis PJ. Hercbergs A, et al. Among authors: mousa sa. Front Endocrinol (Lausanne). 2023 Jan 11;13:1109555. doi: 10.3389/fendo.2022.1109555. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36714596 Free PMC article. Review.

2

What is thyroid function in your just-diagnosed cancer patient?

Hercbergs A, Mousa SA, Lin HY, Davis PJ. Hercbergs A, et al. Among authors: mousa sa. Front Endocrinol (Lausanne). 2023 Feb 17;14:1109528. doi: 10.3389/fendo.2023.1109528. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36875482 Free PMC article.

3

Editorial Expression of Concern: Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles.

Yalcin M, Lin HY, Sudha T, Bharali DJ, Meng R, Tang HY, Davis FB, Stain SC, Davis PJ, Mousa SA. Yalcin M, et al. Among authors: mousa sa. Discov Oncol. 2023 May 22;14(1):75. doi: 10.1007/s12672-023-00668-5. Discov Oncol. 2023. PMID: 37213035 Free PMC article. No abstract available.

4

Pharmacokinetics of fluorobenzyl polyethylene glycol conjugated tetraiodothyroacetic acid (NP751), a novel anticancer thyrointegrin α_vβ₃ antagonist.

Fujioka K, Hay BA, Godugu K, Mousa SA. Fujioka K, et al. Among authors: mousa sa. Front Pharmacol. 2022 Nov 28;13:902141. doi: 10.3389/fphar.2022.902141. eCollection 2022. Front Pharmacol. 2022. PMID: 36518666 Free PMC article.

5

Preclinical assessment of drug-drug interaction of fb-PMT, a novel anti-cancer thyrointegrin αvβ3 antagonist.

Fujioka K, Fekry MI, Rumsey JM, Steiner T, Thompson D, Mousa SA. Fujioka K, et al. Among authors: mousa sa. Clin Transl Sci. 2023 Jun;16(6):987-1001. doi: 10.1111/cts.13504. Epub 2023 Apr 28. Clin Transl Sci. 2023. PMID: 36967488 Free PMC article.

6

Nanoformulated 3'-diindolylmethane modulates apoptosis, migration, and angiogenesis in breast cancer cells.

Harakeh S, Akefe IO, Saber SH, Alamri T, Al-Raddadi R, Al-Jaouni S, Tashkandi H, Qari M, Moulay M, Aldahlawi A, Abd Elmageed ZY, Mousa S. Harakeh S, et al. Heliyon. 2023 Dec 10;10(1):e23553. doi: 10.1016/j.heliyon.2023.e23553. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38187226 Free PMC article.

7

Prevention and treatment of atherothrombosis: Potential impact of nanotechnology.

Nguyen AB, Iqbal O, Block RC, Mousa SA. Nguyen AB, et al. Among authors: mousa sa. Vascul Pharmacol. 2023 Feb;148:107127. doi: 10.1016/j.vph.2022.107127. Epub 2022 Nov 11. Vascul Pharmacol. 2023. PMID: 36375733 Review.

8

A comprehensive review on lipid nanocarrier systems for cancer treatment: fabrication, future prospects and clinical trials.

Kabil MF, Badary OA, Bier F, Mousa SA, El-Sherbiny IM. Kabil MF, et al. Among authors: mousa sa. J Liposome Res. 2024 Mar;34(1):135-177. doi: 10.1080/08982104.2023.2204372. Epub 2023 May 5. J Liposome Res. 2024. PMID: 37144339 Review.

9

Preclinical evaluation of triiodothyronine nanoparticles as a novel therapeutic intervention for resuscitation from cardiac arrest.

Weil BR, Allen SE, Barbaccia T, Wong K, Beaver AM, Slabinski EA, Mellott JG, Taylor Dickinson PC, Mousa SA. Weil BR, et al. Among authors: mousa sa. Resuscitation. 2023 May;186:109735. doi: 10.1016/j.resuscitation.2023.109735. Epub 2023 Feb 16. Resuscitation. 2023. PMID: 36806653

10

Future regenerative medicine developments and their therapeutic applications.

Altyar AE, El-Sayed A, Abdeen A, Piscopo M, Mousa SA, Najda A, Abdel-Daim MM. Altyar AE, et al. Among authors: mousa sa. Biomed Pharmacother. 2023 Feb;158:114131. doi: 10.1016/j.biopha.2022.114131. Epub 2022 Dec 18. Biomed Pharmacother. 2023. PMID: 36538861 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

667 results

Search Page